In a new study from the Baylor University Medical Center, researchers found a three-day course of remdesivir results in a lower risk for hospitalization or death among patients at high risk for COVID-19 progression.
In the study, the team tested nonhospitalized patients with COVID-19 with symptom onset within the previous seven days and with at least one risk factor for disease progression.
Patients were assigned to receive intravenous remdesivir (200 mg on day 1; 100 mg on days 2 and 3) or placebo (279 and 283 patients, respectively).
The researchers found that two patients in the remdesivir group and 15 in the placebo group had COVID-19-related hospitalization or death.
By day 28, 1.6% and 8.3% of patients in the remdesivir and placebo groups, respectively, had a COVID-19-related medically attended the visit. There were no deaths by day 28.
Adverse events occurred in 42.3% and 46.3% of those in the remdesivir and placebo groups, respectively.
The team says in the campaign toward ending the COVID-19 pandemic, these data add yet another option for the treatment of vulnerable patients who are at high risk of severe COVID-19.
If you care about COVID, please read studies about drug combo that could effectively fight COVID-19, and vegetables and coffee that could protect against COVID-19.
For more information about health, please see recent studies about cause of severe inflammation in COVID-19, and results showing Omicron may be less likely to cause severe disease.
The study is published in the New England Journal of Medicine. One author of the study is Robert L. Gottlieb, M.D., Ph.D.
Copyright © 2021 Knowridge Science Report. All rights reserved.
